Aytu biopharma announces exclusive agreement with lupin pharma canada ltd to commercialize adzenys xr-odt(r) and cotempla xr-odt(r) in canada

Once approved by health canada, adzenys and cotempla will be the only orally disintegrating, extended-release tablets for the treatment of adhd commercialized in canada denver, co / accesswire / october 1, 2024 / aytu biopharma, inc. (the "company" or "aytu") (nasdaq:aytu), a pharmaceutical company focused on commercializing novel therapeutics, and lupin pharma canada ltd ("lupin"), a subsidiary of global pharma major lupin limited, today announced the signing of an exclusive collaboration, distribution and supply agreement for aytu's adzenys xr-odt® and cotempla xr-odt® product lines in canada. adzenys xr-odt extended-release orally disintegrating tablets is a prescription medicine used for the treatment of attention deficit hyperactivity disorder ("adhd") in patients 6 years and above and the only brand fda-approved as bioequivalent to adderall xr®.
AYTU Ratings Summary
AYTU Quant Ranking